Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints
September 11, 2017 at 17:50 PM EDT
Regeneron Pharmaceuticals, Inc. and partner Sanofi announced that Dupixent (dupilumab) met its two primary endpoints in a phase III study conducted on patients with uncontrolled, persistent asthma.